FTRE · Fortrea Holdings Inc.

The thesis

Fortrea's margin repair is working on earnings but not yet on revenue, and the shares at a $20.00 close on 2 October 2026 already reflect much of that progress. The third-quarter report, expected around early November, settles the case: it needs backlog above $7.800 billion and the $205 million full-year adjusted earnings floor intact.

Since the 20 September 2026 note, three things changed. UBS initiated coverage on 30 September 2026 with a Neutral rating and a $22 price target, citing margin concerns and below-peer bookings. The company's September calendar of investor conferences ended with the RBC event on 22 September 2026. The chief financial question is settled: Jason Knoblauch has been back in the role since 9 September 2026.

The narrative is maturing: the story is well known, a new analyst has arrived with a target only about 10% above the close, and the shares sit 3.4% below their $20.70 52-week high. A weekly close below $17.40 would break the recovery.

Bullish and bearish views on Fortrea Holdings Inc.

The bull case on Fortrea Holdings Inc. (FTRE), in brief: Earnings guidance was raised. The bear case: Revenue is still shrinking.

Bull case

• Earnings guidance was raised. The 29 July 2026 release reported second-quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $58.7 million against $54.9 million a year earlier. Full-year adjusted EBITDA guidance moved to $205–220 million.
• Orders still exceed revenue. Second-quarter book-to-bill, net bookings divided by revenue, was 1.06x, and the trailing-twelve-month figure was 1.12x (29 July 2026 release). Ratios above 1.0x are what refill the backlog.
• Finance leadership is stable again. Fortrea's Form 8-K filed 10 September 2026 reinstated Knoblauch as chief financial officer effective 9 September 2026 after a settlement. Interim CFO David Smith remains a director.
• Sell-side targets sit above the price. MarketBeat's 1 October 2026 consensus is Hold from 12 brokerages, with an average target of $22.00. Truist's target is $26 with a Buy rating.

Bear case

• Revenue is still shrinking. Second-quarter revenue was $678.2 million, down 4.5% from a year earlier (29 July 2026 release). Backlog was $7.800 billion at 30 June 2026 against $7.846 billion at 31 March 2026.
• Bookings trail competitors. UBS wrote on 30 September 2026 that management's near-term target of 1.10x book-to-bill compares with 1.15x and above at peers. In UBS's sponsor survey, Fortrea received 4% of votes when customers ranked their most-used contract research organisations.
• Leverage limits the upside. Long-term debt was $1,037.2 million against $168.6 million of cash at 30 June 2026. The 2 September 2026 agreement to buy Worldwide Clinical Trials' early-phase operations carries roughly $45 million of cash consideration, and no revenue contribution or closing date was disclosed.
• Customer concentration is high. The top ten customers were 55.4% of second-quarter revenue and the largest was 16.8%, so one cancelled programme can move backlog.

Price setup

The adjusted daily close on 2 October 2026 was $20.00. The 52-week high is $20.70, and the shares gained 14.4% over three months. The 14-day relative strength index (RSI), a momentum gauge where readings above 70 mark overbought conditions, stood at 68.2.

MarketBeat lists a 50-day moving average of $18.77 and a 200-day moving average of $15.46 on 1 October 2026. The close is above both, and the 200-day average is far below the price.

The lowest close of the recent pullback was $17.41 on 14 August 2026. A weekly close below $17.40 would erase the recovery from that level. A close above $20.70 would set a new 52-week high.

Crowding evidence is moderate. Momentum is near overbought, the price is within 3.4% of its high, and the next earnings report falls about five weeks out. Consensus target upside is roughly 10%.

Catalysts, next 30 days

• ~15 October to 22 October 2026, est.: Fortrea typically announces its quarterly results date a few weeks ahead; the confirmed date is not yet published.
• ~5 November 2026, est.: Third-quarter 2026 results, outside the 30-day window but the event the case turns on. The date is unconfirmed.

Elapsed catalysts

• Any date, undated: Closing of the Worldwide Clinical Trials early-phase acquisition, with no closing date or revenue contribution disclosed as of 2 September 2026. (passed 41d ago)

What would change the view

The case breaks if bookings stop refilling the backlog or if the earnings floor gives way. A quarterly book-to-bill below 1.0x, a trailing-twelve-month ratio below 1.10x, a cut to the $205 million adjusted-EBITDA floor, or a further decline in backlog from $7.800 billion would each show that cost cuts are not turning into growth. A new secured debt issue or revolver draw ahead of the 30 June 2028 term loan A maturity would also weaken it.

On price, a weekly close below $17.40 would end the recovery whatever the reports say. A close above $20.70 with rising bookings would strengthen the case. The sample of post-recovery price history is short, so the price signals carry less weight than the third-quarter numbers.

What it trades with

Fortrea trades with other contract research organisations and with biotech funding sentiment, because its revenue depends on sponsors' clinical-trial spending. UBS's coverage notes tie its rating to bookings against peers. Fortrea's debt load makes its shares more sensitive to interest-rate moves than larger competitors. Theme screens often tag it as a drug developer, but it provides trial services and does not own drug candidates.